Johnson & Johnson Reports Strong Long-Term Results For ICOTYDE In Plaque Psoriasis

Johnson & Johnson announced new 52-week Phase 3 data from ICONIC-ADVANCE 1 & 2 and ICONIC-LEAD evaluating ICOTYDE (icotrokinra) in moderate-to-severe plaque psoriasis. ICOTYDE is described as the first targeted oral peptide that blocks the IL‑23 receptor; absent detailed efficacy/safety metrics or regulatory commentary this is a data/catalyst event for J&J’s dermatology franchise but unlikely to move the broader market until full results and next regulatory steps are disclosed.

Analysis

Johnson & Johnson announced new 52-week Phase 3 data from ICONIC-ADVANCE 1 & 2 and ICONIC-LEAD evaluating ICOTYDE (icotrokinra) in moderate-to-severe plaque psoriasis. ICOTYDE is described as the first targeted oral peptide that blocks the IL‑23 receptor; absent detailed efficacy/safety metrics or regulatory commentary this is a data/catalyst event for J&J’s dermatology franchise but unlikely to move the broader market until full results and next regulatory steps are disclosed.